Media Partners
Patient advocacy organizations have long been influential in the drug development landscape. Most recently, they have played a larger role in the regulatory space, and advisory committee meetings are a…
Independent data monitoring committee advises conclusion of study evaluating once-daily dosing of oral edaravone following interim futility analysis JERSEY CITY, N.J. July 31, 2023 – Mitsubishi Tanabe Pharma America, Inc.…
With the help of artificial intelligence, ALS patients are able to preserve their ability to speak. Dr. Jon LaPook has more.
Erin Kunz took a circuitous route to studying the brain. The third year PhD student in Electrical Engineering started her career developing autonomous vehicles at General Motors (GM) — but now…
New research suggests that targeting autoimmune inflammation associated with amyotrophic lateral sclerosis (ALS) using two drugs, one of them already approved for multiple sclerosis, could be a promising approach for…
On a recent crisp June night, as the Chicago Cubs prepare to take on the Pittsburgh Pirates, fans dressed in blue pack Wrigley Stadium’s famous bleachers. Sitting in his wheelchair,…
CAMBRIDGE, Mass., April 25, 2023 (GLOBE NEWSWIRE) — Biogen Inc. (Nasdaq: BIIB) announced today that the U.S. Food and Drug Administration (FDA) has approved QALSODY™ (tofersen) 100 mg/15mL injection for…
NurOwn (BrainStorm Cell Therapeutics) is an investigational therapy made up of autologous mesenchymal stromal cells secreting neurotrophic factors cells (MSC-NTF) for the potential treatment of amyotrophic lateral sclerosis (ALS) and…